WP interview in CEO magazine, page-11

Going it alone with a next generation technology in an enormous market is not only a viable but great alternative than a buyout by an incumbent. Anteris has much more than the groundbreaking TAVR valve currently undergoing FDA pathway, the FDA approved Adapt tissue has already used in tens of thousands of patients worldwide. With available resources and further R&D, the tissue could be further developed and applied to various life saving products in the foreseeable future. It has an existing manufacturing facilities already in production. Recent fundings have been secured from $8 to $15 etc and I would expect the next raise will be at a much higher price than the current share price.
There were some recent promotions in Australia’s media which might put themselves in a better position for more collaboration, support and partnership with local universities, commercial and government entities. Local manufacturing in healthcare sector in Australia could well be a way to go as well from the supply chain disruption over the last few years.

Not advice, DYOR!